ASJC Scopus subject areas
Access to Document
Other files and links
Liposomal cytarabine and daunorubicin (CPX-351/Vyxeos)–associated distinct purpuric subtype of toxic erythema of chemotherapy : A retrospective review of 54 patients. / Stoll, Joseph R.; Battle, Laura; Moy, Andrea; Dusza, Stephen W.; Park, Jae H.; Tallman, Martin S.; Taylor, Justin; Markova, Alina.In: Journal of the American Academy of Dermatology, Vol. 86, No. 1, 01.2022, p. 232-234.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Liposomal cytarabine and daunorubicin (CPX-351/Vyxeos)–associated distinct purpuric subtype of toxic erythema of chemotherapy
T2 - A retrospective review of 54 patients
AU - Stoll, Joseph R.
AU - Battle, Laura
AU - Moy, Andrea
AU - Dusza, Stephen W.
AU - Park, Jae H.
AU - Tallman, Martin S.
AU - Taylor, Justin
AU - Markova, Alina
N1 - Funding Information: Funding sources: Dr Markova was supported by a Dermatology Foundation Career Development Award. This study was also funded in part by a grant from the National Cancer Institute/National Institutes of Health (P30-CA008748) made to the Memorial Sloan Kettering Cancer Center.Dr Park has served on the advisory board of Artiva and has served as a consultant for Amgen, Novartis, Kite Pharma, Intellia, Allogene, Incyte, Takeda, Servier, AstraZeneca, and Autolus. Dr Tallman has served on the advisory board of AbbVie, BioLineRx, Daiichi-Sankyo, Orsenix, KAHR, Rigel, Nohla, Delta Fly Pharma, Tetraphase, Oncolyze, Jazz Pharma, Roche, Biosight; has received research funding from AbbVie, Cellerant, Orsenix, ADC Therapeutics, Biosight, and Glycomimetics, and receives royalties from UpToDate. Dr Markova has served on the advisory board of AstraZeneca and has received research funding from Incyte. Author Stoll and Drs Battle, Moy, Dusza, and Taylor have no conflicts of interest to declare.
PY - 2022/1
Y1 - 2022/1
UR - http://www.scopus.com/inward/record.url?scp=85102742018&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85102742018&partnerID=8YFLogxK
U2 - 10.1016/j.jaad.2021.01.096
DO - 10.1016/j.jaad.2021.01.096
M3 - Article
C2 - 33539850
AN - SCOPUS:85102742018
VL - 86
SP - 232
EP - 234
JO - Journal of the American Academy of Dermatology
JF - Journal of the American Academy of Dermatology
SN - 0190-9622
IS - 1